

## RESOURCES

## PEOPLE

**Saeid Akhtari** has joined Pharsight (Mountain View, CA) as vice president of business development. Previously, he was vice president of sales, marketing, and strategic planning at Pangea Systems.

Amgen (Thousand Oaks, CA) has announced that Nobel Prize winner **David Baltimore** has been elected to its board of directors. Currently president of the California Institute of Technology, Dr. Baltimore was appointed to head the National Institutes of Health AIDS Vaccine Research Committee in 1996.

**Thomas J. Bucknum** has been appointed vice president-general counsel and secretary of Biogen (Cambridge, MA). He has been Biogen's chief corporate counsel and associate general counsel since 1996. Mr. Bucknum joined the company from DuPont Merck, where he served as senior vice president and general counsel. In addition, Biogen also announced that **Anne Marie Cook** will take over as chief corporate counsel. Ms. Cook has been an associate general counsel since 1992.

Dyax (Cambridge, MA) has appointed **Scott Chappel** to the newly created position of senior vice president, research. His most recent position was senior vice president and chief scientist at Serono Laboratories, a division of Ares-Serono.



**Icos** (Bothell, WA) has named former Abbott Laboratories executive vice president and director **Paul N. Clark** as its new CEO and president. He replaces **George B. Rathmann**, who has been Icos's chairman since 1990, and CEO and president since 1991. Dr. Rathmann will remain as chairman.

**Elizabeth M. Greetham** has joined DrugAbuse Sciences' (Menlo Park, CA) management team as chief financial officer. She has been a member of the board since 1998. Previously, Ms. Greetham managed the life sciences investment fund for Weiss, Peck & Greer, an institutional investment management firm in New York.

**Chiron** (Emeryville, CA) has named **Paul J. Hastings** president of its biopharmaceuticals business. Mr. Hastings was formerly president and CEO of LXR Biotechnology and president of Genzyme Therapeutics.

**Celgene** (Warren, NJ) has announced the appointment of **Robert J. Hugin** to the position of CFO and senior vice president. He succeeds **Robert C. Butler**, who retired last year. Prior to Celgene, Mr. Hugin spent 14 years at J.P. Morgan & Co., where he held a number of senior client and market related positions.

**Aclara BioSciences** (Hayward, CA) has announced that **Michael W. Hunkapiller**, president of PE Biosystems Group, has joined its board of directors. Dr. Hunkapiller has been president of PE Biosystems, one of two operating groups within PE Corporation, since June 1998.

**Richard W. Keatinge** has been named vice president of business development of Digital Gene Technologies (La Jolla, CA). He has been a consultant to the company since its inception, and was previously president of his own firm, Keatinge & Associates.

**Gregor K. Mirow** has been appointed head of business development and finance at Micromet GmbH (Martinsried, Germany). Most recently, he was managing director for Rentschler Pharmaceuticals.

**Diane Parks** has been named vice president of marketing at Genentech (S. San Francisco, CA). She has 17 years experience at Marion Laboratories (now Hoechst Marion Roussel), most recently as vice president of marketing.

**Mark W. Schwartz** has joined Trega Biosciences (San Diego, CA) as vice president of commercial operations and chief commercial officer. Most recently, Dr. Schwartz was vice president of marketing and business development for Argonaut Technologies

**Cantab Pharmaceuticals** (Cambridge, UK) has announced the appointment of **John St. Clair Roberts** to the executive board. Dr. Roberts has been medical director at Cantab since joining the company in 1994.

**Norman John Wilkie Russell** has been named president and CEO of Lynx Therapeutics (Hayward, CA). Previously, he held the position of global head of biological enabling science technology at AstraZeneca. Outgoing CEO **Sam Eletr** will remain with the company as chairman of the board.

**Richard A. Waldron** has been appointed vice president and CFO of Genelabs Technologies (Redwood City, CA). Mr. Waldron joins Genelabs from GeneMedicine, where he has been vice president and CFO for the past four years.